Avoid These 10 Resume Mistakes

Posted · Add Comment

Avoid These 10 Resume Mistakes by Katharine Hansen, Ph.D. As a resume writer, I see hundreds of resumes, and the vast majority of them are much weaker than they could be. I see the same mistakes over and over. This article describes the 10 I see most often. All are easy to fix. Don’t Make […]

10 Best Job Interview Tips for Job-Seekers

Posted · Add Comment

10 Best Job Interview Tips for Job-Seekers by Randall S. Hansen, Ph.D. When you have successfully mastered cover letters, resumes, and job applications and are receiving requests for interviews, it’s time to understand how to succeed in the job interview so that you are ever closer to your goal of obtaining one or more job […]

Keytruda

Posted · Add Comment

Keytruda, the drug that helped Jimmy Carter, also protects against lung cancer Researchers have stopped a study of a new lung cancer drug, saying it’s so effective they want to offer it to all the patients in the trial. “This is a huge deal for people with what we call non-small cell lung cancer, which […]

Merck Extends Cancer Immunotherapy Reach to First-Line Lung Cancer Merck’s flagship cancer immunotherapy Keytruda delayed the re-growth of tumors and prolonged survival in patients with newly diagnosed non-small cell lung cancer compared to chemotherapy, the company said Thursday.

Posted · Add Comment

Merck Extends Cancer Immunotherapy Reach to First-Line Lung Cancer Merck’s flagship cancer immunotherapy Keytruda delayed the re-growth of tumors and prolonged survival in patients with newly diagnosed non-small cell lung cancer compared to chemotherapy, the company said Thursday. Merck’s (MRK) flagship cancer immunotherapy Keytruda delayed the re-growth of tumors and prolonged survival in patients with […]

Should Pfizer Buy This Beaten-Down Immuno-Oncology Company?

Posted · Add Comment

This tiny drugmaker could give Pfizer an edge over its immuno-oncology competitors. Bristol-Myers Squibb (NYSE: BMY) and Merck‘s (NYSE:MRK)game-changing(NYSE:MRK)immuno-oncology drugs, Opdivo and Keytruda, respectively, have triggered an avalanche of research into so-called “checkpoint inhibitors” due to their stunning commercial success. For example, AstraZeneca, Pfizer (NYSE:PFE), and Roche have all made significant strides toward bringing their own checkpoint inhibitors to market […]